Letters to the Editor
Vol. 9 No. 1 (2017): Review, Original Articles, Case Reports
Should every patient with MDS get iron chelation – probably yes.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: July 5, 2017
Accepted: July 21, 2017
Accepted: July 21, 2017
2588
Views
904
Downloads
355
HTML
Hematology
Authors
Downloads
Download data is not yet available.
Citations
Angelucci E, Urru SA, Pilo F, Piperno A. Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis. 2017 Mar 1;9:e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017.
Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br. Jr. Haematol. 2017.177:741-750.
Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry .Leuk Res. 2012;36:1067-70.
Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N.Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016 ;35:3577-86.
Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006 ;91:1588-90.
Fibach E, Rachmilewitz EASelective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leuk. Res. 2012;36:962-3.
Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF,Rachmilewitz EA, Hebbel RPDeferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood.199586:2008-13.
Cazzola M, Della Porta MG, Malcovati L.The genetic basis of myelodysplasia and its clinical relevance. Blood.2013 ;122:4021-34.
Prá D, Franke SI, Henriques JA, Fenech M.Iron and genome stability: an update. Mut. Res. 2012;733:92-9.
Gupta M, Madkaikar M, Rao VB, Mishra A, Govindaraj P, Thangaraj K, Ghosh K Mitochondrial DNA variations in myelodysplastic syndrome. Annals . Hematol.2013;92:871-6.
Reddy PL, Shetty VT, Dutt D, York A, Dar S, Mundle SD, Allampallam K, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, Suleman S, Kamal SY, Raza A(2002).Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br. Jour. Haematol.2002;116:564-75.
Nairz M, Schroll A, Demetz E, Tanncevski I, Theurl I, Weiss G.Ride on the ferrous wheel—The cycle of iron in macrophages in health and disease. Immunobiology, 2014. http//dx.doi.org/10.1016/j.imbio.2014.09.010.
Ethics Approval
LettersHow to Cite
“Should every patient with MDS get iron chelation – probably yes”. (2017) Mediterranean Journal of Hematology and Infectious Diseases, 9(1), p. e2017055. doi:10.4084/mjhid.2017.055.
